ArticleESMO open2022

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.

B Tombal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.